triazoles has been researched along with Parkinsonian Disorders in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 13 (54.17) | 29.6817 |
| 2010's | 10 (41.67) | 24.3611 |
| 2020's | 1 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| Contu, L; Costa, G; Morelli, M; Pinna, A; Serra, M | 1 |
| Bédard, D; Frouni, I; Gourdon, JC; Hamadjida, A; Huot, P; Kwan, C; Nuara, SG | 1 |
| Agostinho, P; Andrade, GM; Canas, PM; Carmo, M; Cunha, RA; Duarte, FV; Fernandes, FD; Gonçalves, FQ; Oses, JP; Palmeira, CM; Tomé, AR | 1 |
| Bleickardt, CJ; Boykow, G; Browne, SE; Hill, D; Hodge, LM; Hodgson, RA; Innocent, N; Jayaraman, S; Lis, E; Mullins, DE; Parker, EM; Reynolds, IJ; Rittle, SL; Smith, KM; Yao, L | 1 |
| Ciruela, F; Fernández-Dueñas, V; Gandía, J; Morató, X; Stagljar, I | 1 |
| Borsini, F; Caprioli, A; Di Serio, S; Lombardo, K; Minetti, P; Pace, S; Riccioni, T; Stasi, MA; Vertechy, M | 1 |
| A Figge, D; Standaert, DG | 1 |
| Jalali, A; Kawa, K; Larsen, C; Trevitt, J | 1 |
| Borsini, F; Frau, L; Khairnar, AS; Morelli, M; Schintu, N; Wardas, J | 1 |
| Salamone, JD | 1 |
| Crichton, RR; Della Corte, L; Dexter, DT; Freinbichler, W; Statton, SA; Tipton, KF; Ward, RJ; Weinberger, P; Whitmore, C | 1 |
| Dziubina, A; Gołembiowska, K | 1 |
| Carta, AR; Morelli, M; Pinna, A; Tronci, E | 1 |
| Bastia, E; Chen, JF; Fredduzzi, S; Moratalla, R; Ongini, E; Schwarzschild, MA; Yu, L | 1 |
| Costentin, J; El Yacoubi, M; Vaugeois, JM | 1 |
| Benwell, K; Cliffe, IA; Dourish, CT; Gillespie, RJ; Knight, AR; Lerpiniere, J; Misra, A; Pratt, RM; Revell, D; Upton, R; Weiss, SM | 1 |
| Chen, L; Engber, T; Grant, D; Hetu, G; Huang, C; Jin, X; Kumaravel, G; Peng, B; Petter, RC; Phadke, D; Reilly, J; Smits, G; Tam, S; Vu, CB; Zhang, J | 1 |
| Baraldi, PG; Fenu, S; Morelli, M; Simola, N; Tabrizi, MA | 1 |
| Dexter, DT; Dhankot, A; Gillies, GE; McArthur, S; Murray, HE | 1 |
| Jenner, P; Ramsay Croft, N; Rose, S | 1 |
| Beilstein, M; Castagnoli, K; Castagnoli, N; Chen, JF; Petzer, JP; Schwarzschild, MA; Sonsalla, PK; Staal, R; Xu, K; Xu, YH | 1 |
| Konieczny, J; Lorenc-Koci, E; Wardas, J | 1 |
| Morelli, M; Pinna, A | 1 |
| Jerome, L | 1 |
1 review(s) available for triazoles and Parkinsonian Disorders
| Article | Year |
|---|---|
Preladenant, a novel adenosine A(2A) receptor antagonist for the potential treatment of parkinsonism and other disorders.
Topics: Adenosine A2 Receptor Antagonists; Animals; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Mice; Parkinsonian Disorders; Pyrimidines; Rats; Triazoles | 2010 |
23 other study(ies) available for triazoles and Parkinsonian Disorders
| Article | Year |
|---|---|
Neuroinflammation and L-dopa-induced abnormal involuntary movements in 6-hydroxydopamine-lesioned rat model of Parkinson's disease are counteracted by combined administration of a 5-HT
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Calcium-Binding Proteins; Caudate Nucleus; Dyskinesia, Drug-Induced; Glial Fibrillary Acidic Protein; Interleukin-10; Interleukin-1beta; Levodopa; Microfilament Proteins; Neuroinflammatory Diseases; Oxidopamine; Parkinsonian Disorders; Pars Compacta; Piperazines; Putamen; Pyrimidines; Rats; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT1B; Serotonin 5-HT1 Receptor Agonists; Triazoles; Tumor Necrosis Factor-alpha | 2021 |
Nefazodone reduces dyskinesia, but not psychosis-like behaviours, in the parkinsonian marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Callithrix; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Parkinsonian Disorders; Piperazines; Psychoses, Substance-Induced; Triazoles | 2018 |
Enhanced ATP release and CD73-mediated adenosine formation sustain adenosine A
Topics: 5'-Nucleotidase; Adenosine; Adenosine A2 Receptor Antagonists; Adenosine Diphosphate; Adenosine Triphosphate; Animals; Cell Line, Tumor; Humans; Male; Oxidopamine; Parkinsonian Disorders; Pyrimidines; Rats, Wistar; Receptor, Adenosine A2A; Triazoles | 2019 |
Effects of the selective adenosine A2A receptor antagonist, SCH 412348, on the parkinsonian phenotype of MitoPark mice.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; gamma-Aminobutyric Acid; Globus Pallidus; Hypokinesia; Male; Mice; Mice, Inbred Strains; Motor Activity; Parkinsonian Disorders; Protein Binding; Pyrimidines; Receptor, Adenosine A2A; Rotarod Performance Test; Triazoles | 2014 |
Adenosine A2A receptor-mediated control of pilocarpine-induced tremulous jaw movements is Parkinson's disease-associated GPR37 receptor-dependent.
Topics: Adenosine A2 Receptor Antagonists; Animals; Jaw; Male; Mice, Inbred C57BL; Mice, Knockout; Movement; Muscarinic Antagonists; Parkinsonian Disorders; Pilocarpine; Pyrimidines; Receptor, Adenosine A2A; Receptors, G-Protein-Coupled; Tremor; Triazoles; Tropicamide | 2015 |
Animal models of Parkinson׳s disease: Effects of two adenosine A2A receptor antagonists ST4206 and ST3932, metabolites of 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine (ST1535).
Topics: Adenine; Adenosine A2 Receptor Antagonists; Administration, Oral; Animals; Antiparkinson Agents; Basal Ganglia; Binding, Competitive; Catalepsy; Cyclic AMP; Disease Models, Animal; Dose-Response Relationship, Drug; Haloperidol; HEK293 Cells; Humans; Injections, Intraperitoneal; Ligands; Male; Mice; Motor Activity; Oxidopamine; Parkinsonian Disorders; Protein Binding; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Transfection; Triazoles | 2015 |
Dysregulation of BET proteins in levodopa-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Azepines; Chromatin Immunoprecipitation; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Protein Domains; Proteins; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; RNA, Messenger; Transcription, Genetic; Triazoles | 2017 |
Differential effects of adenosine antagonists in two models of parkinsonian tremor.
Topics: Adenosine; Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Animals; Caffeine; Cholinergic Agonists; Disease Models, Animal; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Drug Synergism; Jaw; Male; Parkinsonian Disorders; Pimozide; Purinergic P1 Receptor Antagonists; Pyrimidines; Rats; Rats, Sprague-Dawley; Tacrine; Theophylline; Tremor; Triazoles | 2009 |
Neuroprotective and anti-inflammatory effects of the adenosine A(2A) receptor antagonist ST1535 in a MPTP mouse model of Parkinson's disease.
Topics: Adenine; Adenosine A2 Receptor Antagonists; Animals; Anti-Inflammatory Agents; Brain; Immunohistochemistry; Male; Mice; Mice, Inbred C57BL; Microglia; Nerve Degeneration; Neuroprotective Agents; Parkinsonian Disorders; Triazoles | 2011 |
Clinically available iron chelators induce neuroprotection in the 6-OHDA model of Parkinson's disease after peripheral administration.
Topics: Animals; Benzoates; Brain; Deferasirox; Deferiprone; Deferoxamine; Free Radicals; Immunohistochemistry; Injections, Intraventricular; Iron Chelating Agents; Male; Microdialysis; Neuroprotective Agents; Parkinsonian Disorders; Pyridones; Rats; Rats, Sprague-Dawley; Sorbic Acid; Triazoles | 2011 |
Effect of adenosine A(2A) receptor antagonists and L-DOPA on hydroxyl radical, glutamate and dopamine in the striatum of 6-OHDA-treated rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine A2 Receptor Antagonists; Animals; Benserazide; Caffeine; Dopamine; Glutamic Acid; Hydroxyl Radical; Levodopa; Male; Microdialysis; Neostriatum; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Receptor, Adenosine A2A; Triazines; Triazoles | 2012 |
Adenosine A2A and dopamine receptor interactions in basal ganglia of dopamine denervated rats.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Basal Ganglia; Behavior, Animal; Denervation; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Gene Expression; Glutamate Decarboxylase; Isoenzymes; Levodopa; Motor Activity; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Pyrimidines; Rats; Receptor, Adenosine A2A; Receptors, Dopamine; RNA, Messenger; Time; Triazoles | 2003 |
Adenosine A2A receptors in neuroadaptation to repeated dopaminergic stimulation: implications for the treatment of dyskinesias in Parkinson's disease.
Topics: Adenosine A2 Receptor Antagonists; Amphetamine; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dopamine; Dopamine Agonists; Drug Tolerance; Dyskinesia, Drug-Induced; Humans; Levodopa; Mice; Mice, Knockout; Neurons; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Purines; Pyrimidines; Receptor, Adenosine A2A; Synapses; Triazoles | 2003 |
Adenosine A2A receptors and depression.
Topics: Adenosine; Adenosine A2 Receptor Antagonists; Animals; Antidepressive Agents; Behavior, Animal; Caffeine; Depression; Disease Models, Animal; Dopamine Antagonists; Drug Interactions; Haloperidol; Mice; Mice, Knockout; Motor Activity; Neurotransmitter Agents; Parkinsonian Disorders; Purines; Pyrimidines; Receptor, Adenosine A2A; Triazines; Triazoles | 2003 |
Discovery of nonxanthine adenosine A2A receptor antagonists for the treatment of Parkinson's disease.
Topics: Adenosine; Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Binding, Competitive; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Drug Evaluation, Preclinical; Humans; Ligands; Mefloquine; Mice; Motor Activity; Neuroprotective Agents; Parkinsonian Disorders; Phenethylamines; Purines; Pyrimidines; Radioligand Assay; Rats; Triazines; Triazoles | 2003 |
Piperazine derivatives of [1,2,4]triazolo[1,5-a][1,3,5]triazine as potent and selective adenosine A2a receptor antagonists.
Topics: Adenosine A2 Receptor Antagonists; Administration, Oral; Animals; Antiparkinson Agents; Biological Availability; Brain; Catalepsy; Heterocyclic Compounds, 2-Ring; In Vitro Techniques; Male; Mice; Parkinsonian Disorders; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Structure-Activity Relationship; Triazines; Triazoles | 2004 |
Blockade of adenosine A2A receptors antagonizes parkinsonian tremor in the rat tacrine model by an action on specific striatal regions.
Topics: Adenosine A2 Receptor Antagonists; Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Jaw; Male; Movement; Parkinsonian Disorders; Piperazines; Pyrimidines; Rats; Rats, Sprague-Dawley; Tacrine; Time Factors; Trema; Triazoles | 2004 |
Striatal susceptibility to a dopaminergic neurotoxin is independent of sex hormone effects on cell survival and DAT expression but is exacerbated by central aromatase inhibition.
Topics: Anastrozole; Animals; Aromatase; Aromatase Inhibitors; Cell Survival; Corpus Striatum; Dopamine; Dopamine Plasma Membrane Transport Proteins; Drug Resistance; Estrogens; Female; Male; Nerve Degeneration; Neural Pathways; Neuronal Plasticity; Neurotoxins; Nitriles; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Sex Characteristics; Substantia Nigra; Triazoles | 2007 |
The novel adenosine A2a antagonist ST1535 potentiates the effects of a threshold dose of l-dopa in unilaterally 6-OHDA-lesioned rats.
Topics: Adenine; Adenosine; Adenosine A2 Receptor Antagonists; Animals; Brain; Disease Models, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Drug Synergism; Exploratory Behavior; Levodopa; Male; Movement; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Receptor, Adenosine A2A; Sympatholytics; Triazoles | 2007 |
Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Caffeine; Catechols; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Immunity, Innate; Injections, Intraperitoneal; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Neuroprotective Agents; Parkinsonian Disorders; Purinergic P1 Receptor Antagonists; Purines; Pyrimidines; Receptor, Adenosine A2A; Receptors, Purinergic P1; Theobromine; Triazoles; Xanthines | 2001 |
SCH 58261, an A(2A) adenosine receptor antagonist, counteracts parkinsonian-like muscle rigidity in rats.
Topics: Adrenergic Uptake Inhibitors; Animals; Ankle Joint; Dopamine Agents; Dopamine Antagonists; Drug Combinations; Electromyography; Haloperidol; Levodopa; Male; Muscle Contraction; Muscle Rigidity; Muscle, Skeletal; Neostriatum; Neuroprotective Agents; Parkinsonian Disorders; Purinergic P1 Receptor Antagonists; Pyrimidines; Rats; Rats, Wistar; Receptor, Adenosine A2A; Receptors, Purinergic P1; Reserpine; Triazoles | 2001 |
Interaction between dopamine and adenosine A2A receptors as a basis for the treatment of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Denervation; Dopamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Drug Tolerance; Levodopa; Male; Motor Activity; Neostriatum; Neural Pathways; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Purinergic P1 Receptor Antagonists; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Receptors, Purinergic P1; Substantia Nigra; Sympatholytics; Triazoles | 2001 |
Bupropion and drug-induced parkinsonism.
Topics: Bupropion; Depressive Disorder, Major; Drug Interactions; Drug Therapy, Combination; Humans; Male; Middle Aged; Neurologic Examination; Parkinsonian Disorders; Piperazines; Triazoles | 2001 |